HK1247828A1 - 多功能兩性離子聚合物共軛物 - Google Patents
多功能兩性離子聚合物共軛物Info
- Publication number
- HK1247828A1 HK1247828A1 HK18107293.9A HK18107293A HK1247828A1 HK 1247828 A1 HK1247828 A1 HK 1247828A1 HK 18107293 A HK18107293 A HK 18107293A HK 1247828 A1 HK1247828 A1 HK 1247828A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- polymer conjugates
- zwitterionic polymer
- multifunctional
- multifunctional zwitterionic
- conjugates
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/56—Acrylamide; Methacrylamide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/06—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
- C08F226/10—N-Vinyl-pyrrolidone
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F230/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
- C08F230/04—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal
- C08F230/08—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
- C08F230/085—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon the monomer being a polymerisable silane, e.g. (meth)acryloyloxy trialkoxy silanes or vinyl trialkoxysilanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28812709P | 2009-12-18 | 2009-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1247828A1 true HK1247828A1 (zh) | 2018-10-05 |
Family
ID=44167643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18107293.9A HK1247828A1 (zh) | 2009-12-18 | 2018-06-04 | 多功能兩性離子聚合物共軛物 |
Country Status (15)
Country | Link |
---|---|
US (5) | US8765432B2 (zh) |
EP (3) | EP2512462B1 (zh) |
JP (5) | JP5760007B2 (zh) |
KR (1) | KR101852044B1 (zh) |
CN (2) | CN102811713B (zh) |
AU (1) | AU2010330727B2 (zh) |
BR (1) | BR112012014556B1 (zh) |
CA (2) | CA2783615C (zh) |
CL (1) | CL2012001621A1 (zh) |
CO (1) | CO6592052A2 (zh) |
DK (2) | DK2512462T3 (zh) |
HK (1) | HK1247828A1 (zh) |
MX (1) | MX346423B (zh) |
PT (2) | PT2512462T (zh) |
WO (2) | WO2011075185A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100166700A1 (en) | 2006-02-28 | 2010-07-01 | Oligasis Corporation | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation |
CA2665493A1 (en) | 2006-08-07 | 2008-02-14 | University Of Washington | Mixed charge copolymers and hydrogels |
WO2011075185A1 (en) * | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
KR20180130008A (ko) * | 2010-04-15 | 2018-12-05 | 올리가시스 | 고분자량 쌍성이온-함유 중합체 |
CN102977275B (zh) * | 2011-09-07 | 2014-12-10 | 佛山市博新生物科技有限公司 | 一种经过预处理的含有磷酰胆碱基团的单体改善吸附树脂生物相容性的应用 |
WO2013059137A1 (en) * | 2011-10-17 | 2013-04-25 | Oligasis | High molecular weight zwitterion-containing polymers |
JP6234064B2 (ja) * | 2012-05-23 | 2017-11-22 | キヤノン株式会社 | 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法 |
WO2014004278A1 (en) * | 2012-06-26 | 2014-01-03 | The Curators Of The University Of Missouri | Photocleavable drug conjugates |
CN102875733B (zh) * | 2012-10-25 | 2014-06-11 | 西安科技大学 | 具有仿细胞外层膜结构的纳米颗粒及其制备方法 |
WO2014144744A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Aptamer methods and compositions |
PT3041513T (pt) | 2013-09-08 | 2020-09-07 | Kodiak Sciences Inc | Conjugados de polímeros zwiteriónicos com fator viii |
WO2015073579A1 (en) * | 2013-11-12 | 2015-05-21 | University Of Washington Through Its Center For Commercialization | Random copolymer therapeutic agent carriers and assemblies thereof |
EP3079668A1 (en) * | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US10588564B2 (en) | 2014-09-30 | 2020-03-17 | Moein Health, LLC | Method and kit for diagnosing and treating neoplastic tissue |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
US10398788B2 (en) * | 2014-10-24 | 2019-09-03 | Canon Kabushiki Kaisha | Polymer and contrast agent for photoacoustic imaging including the polymer |
IL243285A0 (en) | 2015-12-22 | 2016-04-21 | Yeda Res & Dev | Analogues of lipids and liposomes containing them |
RU2744860C2 (ru) * | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
EP3558384A4 (en) * | 2016-12-23 | 2020-08-19 | Commonwealth Scientific and Industrial Research Organisation | BIOCOMPATIBLES AND HYDROPHILIC POLYMER CONJUGATE FOR THE TARGETED RELEASE OF AN ACTIVE SUBSTANCE |
CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
EP3720506A4 (en) * | 2017-12-04 | 2021-09-29 | Lecouteur, David | COMPOSITIONS AND METHODS FOR MODULATING THE WINDOWS OF HEPATIC ENDOTHELIAL CELLS |
JP2019112533A (ja) * | 2017-12-24 | 2019-07-11 | 国立大学法人千葉大学 | 貴金属分離回収可能なコポリマー及びそのコポリマーを用いた貴金属回収方法 |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
EP3831909A1 (en) * | 2019-12-03 | 2021-06-09 | Université de Strasbourg | Luminescent zwitterionic polymeric nanoparticles |
JP7425405B2 (ja) | 2020-03-13 | 2024-01-31 | 日油株式会社 | 共重合体およびその用途 |
IL297129A (en) * | 2020-04-06 | 2022-12-01 | Tiba Biotech Llc | leading to efficient application of nucleic acids |
CN112033943B (zh) * | 2020-08-17 | 2021-03-30 | 中南民族大学 | 一种基于量子点-铜离子荧光基底传感器的精氨酸检测方法 |
WO2022235329A1 (en) * | 2021-05-06 | 2022-11-10 | University Of South Carolina | Brain-targeted antibody nanoparticle for neurodegenerative diseases therapy |
JPWO2022255204A1 (zh) * | 2021-06-01 | 2022-12-08 | ||
AU2022328663A1 (en) | 2021-08-16 | 2024-02-15 | Tiba Biotech Llc | Nanoparticle compositions containing sugar functionalized nucleic acid carriers |
CN114410735B (zh) * | 2022-01-25 | 2023-10-27 | 河南中医药大学 | 以氨磷汀为底物利用atrp信号放大策略检测碱性磷酸酶的电化学试剂盒及使用方法 |
Family Cites Families (241)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
AU5772886A (en) | 1985-04-12 | 1986-11-05 | Genetics Institute Inc. | Novel procoagulant proteins |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体 |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5162218A (en) | 1988-11-18 | 1992-11-10 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0584082B1 (en) | 1991-01-31 | 2000-05-31 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
CA2112411C (en) * | 1991-07-05 | 2001-01-02 | Roderick W. J. Bowers | Polymeric surface coatings |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
CA2124690C (en) | 1992-10-02 | 2007-09-11 | Thomas Osterberg | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
GB9301702D0 (en) | 1993-01-28 | 1993-03-17 | Biocompatibles Ltd | New materials |
GB9301701D0 (en) | 1993-01-28 | 1993-03-17 | Biocompatibles Ltd | New zwitterionic materials |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
GB9324033D0 (en) | 1993-11-23 | 1994-01-12 | Biocompatibles Ltd | Ethylenically unsaturated compounds |
US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
US5763548A (en) | 1995-03-31 | 1998-06-09 | Carnegie-Mellon University | (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization |
US6541580B1 (en) | 1995-03-31 | 2003-04-01 | Carnegie Mellon University | Atom or group transfer radical polymerization |
GB9521234D0 (en) | 1995-10-16 | 1995-12-20 | Biocompatibles Ltd | Synthesis of polymerisable phospho diesters |
AU697710B2 (en) | 1995-10-16 | 1998-10-15 | Biocompatibles Limited | Oxidation of phosphorus compounds |
US5807937A (en) | 1995-11-15 | 1998-09-15 | Carnegie Mellon University | Processes based on atom (or group) transfer radical polymerization and novel (co) polymers having useful structures and properties |
US5663425A (en) | 1996-01-26 | 1997-09-02 | Lignotech Usa, Inc. | Production of acid soluble humates |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5789487A (en) | 1996-07-10 | 1998-08-04 | Carnegie-Mellon University | Preparation of novel homo- and copolymers using atom transfer radical polymerization |
US6156884A (en) | 1996-08-05 | 2000-12-05 | Prolinx, Inc. | Bifunctional boronic compound complexing reagents and complexes |
JPH10139832A (ja) * | 1996-11-08 | 1998-05-26 | Nof Corp | 共重合体およびグルコースセンサー |
US7125938B2 (en) | 1997-03-11 | 2006-10-24 | Carnegie Mellon University | Atom or group transfer radical polymerization |
JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗vegf抗体 |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
JP3052923B2 (ja) | 1997-05-30 | 2000-06-19 | 日本油脂株式会社 | (メタ)アクリレート誘導体の製造方法 |
KR20010031190A (ko) | 1997-10-16 | 2001-04-16 | 아비게닉스, 인코포레이티드 | 조류 트랜스제네시스용 매그넘-특이적 프로모터를함유하는 벡터 |
CN1295680A (zh) | 1998-01-30 | 2001-05-16 | 第一化学公司 | 含有马来酰亚胺的光致聚合组合物及其使用方法 |
JP4162284B2 (ja) | 1998-02-04 | 2008-10-08 | 日油株式会社 | 洗浄剤組成物 |
US6121371A (en) | 1998-07-31 | 2000-09-19 | Carnegie Mellon University | Application of atom transfer radical polymerization to water-borne polymerization systems |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6159942A (en) | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
JP4145403B2 (ja) * | 1998-09-29 | 2008-09-03 | 日油株式会社 | 免疫学的活性物質測定用高分子/酵素結合体 |
US6781030B1 (en) | 1998-11-02 | 2004-08-24 | Trustee Of Tufts College, Ballou Hall | Methods for cloning mammals using telophase oocytes |
AU2200100A (en) | 1998-12-21 | 2000-07-12 | Genencor International, Inc. | Chemically modified enzymes with multiple charged variants |
AU4195100A (en) | 1999-04-05 | 2000-10-23 | Research Foundation Of State University Of New York, The | Graft, graft-block, block-graft, and star-shaped copolymers and methods of making them |
FR2794459B1 (fr) | 1999-05-19 | 2004-09-03 | Atofina | Polyalcoxyamines issues de nitroxydes beta-substitues |
US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
ES2317843T3 (es) | 1999-07-13 | 2009-05-01 | Bolder Biotechnology, Inc. | Proteinas de fusion de eritropoyetina-inmunoglobulina. |
US7049373B2 (en) | 1999-08-06 | 2006-05-23 | Carnegie Mellon University | Process for preparation of graft polymers |
US6803438B1 (en) | 1999-09-08 | 2004-10-12 | Polytherics Limited | Uniform molecular weight polymers |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6348554B1 (en) | 1999-11-30 | 2002-02-19 | Rohmax Additives Gmbh | Method for preparation of a liquid polymer composition and use of this composition |
GB9928956D0 (en) | 1999-12-07 | 2000-02-02 | Malik Navid | Internally supported biomimetic coating systems |
IL144815A (en) | 2000-08-11 | 2005-07-25 | Sumitomo Chemical Co | Process for producing carbonyl or hydroxy compound |
AU2001296670A1 (en) | 2000-10-06 | 2002-04-15 | Carnegie-Mellon University | A catalyst system for controlled polymerization |
JP5049452B2 (ja) * | 2000-10-06 | 2012-10-17 | バイオコンパティブルズ ユーケー リミテッド | 両性イオン重合体 |
AU2002216619A1 (en) | 2000-10-06 | 2002-04-15 | Carnegie-Mellon University | Polymerization process for ionic monomers |
US6627314B2 (en) | 2000-10-06 | 2003-09-30 | Carnegie Mellon University | Preparation of nanocomposite structures by controlled polymerization |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002081372A2 (en) | 2001-04-06 | 2002-10-17 | Carnegie Mellon University | A process for the preparation of nanostructured materials |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
WO2003021253A2 (de) | 2001-08-27 | 2003-03-13 | Zeptosens Ag | Bionalytische erkennungsoberfläche mit optimierter dichte der erkennungselemente |
JP2003064132A (ja) | 2001-08-28 | 2003-03-05 | Nof Corp | 重合体、製造方法および乳化・分散剤 |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
SE523617C2 (sv) | 2001-10-01 | 2004-05-04 | Sandvik Ab | Skär för spånavskiljande bearbetning försedd med spånbrytande geometri |
WO2003031481A2 (en) | 2001-10-12 | 2003-04-17 | Carnegie Mellon University | Simultaneous reverse and normal initiation of atrp |
AU2002351471A1 (en) | 2001-10-12 | 2003-04-22 | Carnegie Mellon University | Process for monomer sequence control in polymerizations |
US6964859B2 (en) | 2001-10-16 | 2005-11-15 | Massachusetts Institute Of Technology | Suppressor tRNA system |
AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
US8048408B2 (en) | 2002-01-16 | 2011-11-01 | Biocompatibles Uk Limited | Polymer conjugates |
WO2003074026A1 (en) | 2002-03-07 | 2003-09-12 | Biocompatibles Uk Limited | Drug carriers comprising amphiphilic block copolymers |
DE60334779D1 (en) | 2002-03-07 | 2010-12-16 | Biocompatibles Uk Ltd | Mit nucleinsäure complexierte block-copolymere |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7196142B2 (en) | 2002-04-04 | 2007-03-27 | The University Of Akron | Polyisobutylene-based block anionomers and cationomers and synthesis thereof |
JP4248189B2 (ja) * | 2002-04-09 | 2009-04-02 | 株式会社資生堂 | ホスホリルコリン基含有多糖類及びその製造方法 |
US20050180945A1 (en) | 2002-05-21 | 2005-08-18 | Chaikof Elliot L. | Multivalent polymers with chan-terminating binding groups |
ES2566761T3 (es) | 2002-05-30 | 2016-04-15 | The Scripps Research Institute | Ligación de azidas y acetilenos catalizada por cobre |
CA2494105C (en) | 2002-07-31 | 2013-04-02 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1534764B1 (en) | 2002-08-09 | 2014-07-16 | Carnegie Mellon University | Polymers, supersoft elastomers and methods for preparing the same |
US20060165804A1 (en) | 2002-09-25 | 2006-07-27 | Lewis Andrew L | Polymer compositions for administration to animals |
US7737237B2 (en) | 2002-11-07 | 2010-06-15 | Phodia Chimie | Controlled structure copolymer comprising an amphoteric or zwitterionic part |
US20070111279A1 (en) | 2002-11-13 | 2007-05-17 | Procell, Inc. | Production of recombinant therapeutic bioscavengers against chemical and biological agents |
GB0301014D0 (en) | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
JPWO2004065418A1 (ja) | 2003-01-20 | 2006-06-29 | 中外製薬株式会社 | 抗pci中和抗体 |
EP1590388A2 (en) | 2003-02-05 | 2005-11-02 | Biocompatibles UK Limited | Block copolymers |
SI2236154T1 (en) | 2003-02-10 | 2018-08-31 | Biogen Ma Inc. | THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION |
ES2347959T3 (es) | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer. |
WO2004091494A2 (en) | 2003-04-11 | 2004-10-28 | Pr Pharmaceuticals Inc. | Method for preparation of site-specific protein conjugates |
MX369959B (es) | 2003-05-14 | 2019-11-27 | Immunogen Inc | Composicion de farmaco conjugado. |
AU2004251602B2 (en) * | 2003-05-23 | 2010-05-13 | Nektar Therapeutics | PEG derivatives having an amidocarbonate linkage |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
CN1208358C (zh) | 2003-07-31 | 2005-06-29 | 上海交通大学 | 含多羟基官能团多臂星状超支化聚合物刷及其制备方法 |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
WO2005020972A2 (en) | 2003-08-27 | 2005-03-10 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of ocular neovascular disorders |
EP2626083A1 (en) | 2003-09-17 | 2013-08-14 | Nektar Therapeutics | Multi-arm polymer prodrugs |
AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
PL2256134T3 (pl) | 2003-11-13 | 2014-06-30 | Hanmi Science Co Ltd | Fragment Fc Ig do nośnika leku i sposób jego wytwarzania |
ES2445585T3 (es) | 2003-12-16 | 2014-03-04 | Nektar Therapeutics | Composiciones monodispersas de naloxol PEGilado |
US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
KR100593443B1 (ko) | 2004-02-11 | 2006-06-28 | 삼성전자주식회사 | 트랜지스터들 및 그 제조방법들 |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
JP4727938B2 (ja) | 2004-02-24 | 2011-07-20 | 泰彦 岩崎 | リビングラジカル重合開始基を持つポリリン酸の製造方法および用途 |
WO2005087808A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
JP4727941B2 (ja) | 2004-03-12 | 2011-07-20 | 泰彦 岩崎 | 生分解性重合体の製造方法および用途 |
US20050208093A1 (en) | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US7863238B2 (en) * | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
JP5222559B2 (ja) | 2004-10-15 | 2013-06-26 | シアトル ジェネティックス, インコーポレイテッド | 癌および免疫障害の処置および予防のための抗cd70抗体ならびにその使用 |
EP1824988B1 (en) | 2004-11-12 | 2017-04-19 | Bayer HealthCare LLC | Site-directed modification of fviii |
US7214759B2 (en) | 2004-11-24 | 2007-05-08 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
US20090249503A1 (en) | 2004-12-06 | 2009-10-01 | Bolder Biotechnology, Inc. | Enzyme conjugates for use as detoxifying agents |
TW200635608A (en) | 2004-12-15 | 2006-10-16 | Neuralab Ltd | Aβ antibodies for use in improving cognition |
DE602005001922T2 (de) | 2004-12-18 | 2007-12-06 | Haldor Topsoe A/S | Verfahren zur Regelung der Zugabe eines Reduktionsmittels in das Abgas einer Brennkraftmaschine |
EP1858928A2 (en) | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Anti-m-csf antibody compositions having reduced levels of endotoxin |
US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
WO2006118547A1 (en) | 2005-04-29 | 2006-11-09 | Agency For Science, Technology And Research | Hyperbranched polymers and their applications |
US20070005130A1 (en) | 2005-06-29 | 2007-01-04 | Thierry Glauser | Biodegradable polymer for coating |
WO2008020827A2 (en) | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7893173B2 (en) | 2005-08-26 | 2011-02-22 | Carnegie Mellon University | Polymerization process with catalyst reactivation |
JP5096363B2 (ja) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Glp−1のポリマ複合体 |
US7906134B2 (en) * | 2005-12-21 | 2011-03-15 | Abbott Laboratories | Room temperature-curable polymers |
DE102006009004A1 (de) | 2006-02-23 | 2007-09-06 | Sustech Gmbh & Co. Kg | Multifunktionelle sternförmige Präpolymere, deren Herstellung und Verwendung |
US20100166700A1 (en) | 2006-02-28 | 2010-07-01 | Oligasis Corporation | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation |
JP2007263935A (ja) | 2006-03-30 | 2007-10-11 | Canon Inc | 磁性マーカー及びその製造方法 |
JP2009533519A (ja) | 2006-04-14 | 2009-09-17 | インターフェース バイオロジクス,インコーポレーテッド | グラフトポリマーおよびその使用 |
EP2018437A2 (en) | 2006-05-02 | 2009-01-28 | Allozyne, Inc. | Non-natural amino acid substituted polypeptides |
JP5030036B2 (ja) * | 2006-05-23 | 2012-09-19 | 一彦 石原 | 生体成分固定化ポリマー組成物および三次元架橋体 |
US9738745B2 (en) | 2006-06-29 | 2017-08-22 | Life Technologies As | Particles containing multi-block polymers |
US20080008736A1 (en) * | 2006-07-06 | 2008-01-10 | Thierry Glauser | Random copolymers of methacrylates and acrylates |
WO2008006912A2 (en) | 2006-07-14 | 2008-01-17 | Biocompatibles Uk Limited | Polymer |
KR100808116B1 (ko) | 2006-08-22 | 2008-03-03 | 전남대학교산학협력단 | 미생물 점착 방지용 공중합체 수지 코팅재 |
US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
JP5111016B2 (ja) | 2006-11-01 | 2012-12-26 | 三井化学株式会社 | 表面親水性ポリオレフィン成形体およびその製造方法 |
WO2008058021A2 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
WO2008064058A2 (en) | 2006-11-21 | 2008-05-29 | Abbott Laboratories | Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings |
CA2699837C (en) | 2006-12-01 | 2017-06-13 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
US7651527B2 (en) | 2006-12-15 | 2010-01-26 | Medtronic Vascular, Inc. | Bioresorbable stent |
JP5419709B2 (ja) | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗il−13抗体製剤およびその使用 |
AR065092A1 (es) | 2007-02-01 | 2009-05-13 | Genentech Inc | TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS |
EP2118150B1 (en) | 2007-02-14 | 2015-09-23 | Biocompatibles UK Limited | Derivatisation of biological molecules |
JP5383514B2 (ja) | 2007-03-12 | 2014-01-08 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー−抗ヒスタミン複合体 |
EP2131865B1 (en) | 2007-03-12 | 2014-12-17 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
CN101053681B (zh) | 2007-04-10 | 2010-05-19 | 天津大学 | 用于血管栓塞材料的温敏性MPC-b-NIPAM二嵌段星型共聚物及制备方法和应用 |
BRPI0810374A2 (pt) | 2007-04-17 | 2014-10-29 | Imclone Llc | Inibidores específicos do pdgfrbeta |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
WO2008144248A1 (en) * | 2007-05-14 | 2008-11-27 | Tyco Healthcare Group Lp | Furanone copolymers |
JP5019524B2 (ja) * | 2007-06-01 | 2012-09-05 | 国立大学法人 東京大学 | 新規ポリ(メタ)アクリレート共重合体ならびに小胞体及びゴルジ体への送達方法 |
DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
JP2009042617A (ja) | 2007-08-10 | 2009-02-26 | Canon Inc | 静電荷像現像用トナー及びその製造方法 |
US7943370B2 (en) | 2007-08-23 | 2011-05-17 | Canon Kabushiki Kaisha | Structure, target substance detection element and target substance detection kit |
ES2450755T3 (es) | 2007-10-19 | 2014-03-25 | Genentech, Inc. | Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco |
AU2008314697B2 (en) | 2007-10-22 | 2013-08-29 | Merck Serono S.A. | Single IFN-beta fused to a mutated lgG Fc fragment |
JP2009114283A (ja) | 2007-11-05 | 2009-05-28 | Asahi Kasei Chemicals Corp | 吸引用シートおよびそれを用いた装置 |
US20110059176A1 (en) | 2007-11-22 | 2011-03-10 | The University Of Tokyo | Material for preventing tissue adhesion and material for preventing joint contracture |
KR20100107501A (ko) | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
WO2009117531A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
PT2281006T (pt) | 2008-04-30 | 2017-12-06 | Immunogen Inc | Agentes de reticulação e as suas utilizações |
JP5575116B2 (ja) | 2008-05-15 | 2014-08-20 | ビオコムパトイブルエス ユーケー リミテド | 細胞内抗体送達 |
US8187623B2 (en) * | 2008-06-25 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical copolymers |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
JP2010117189A (ja) | 2008-11-12 | 2010-05-27 | Sumitomo Bakelite Co Ltd | 生理活性物質固定化用基板 |
AU2009324490A1 (en) | 2008-12-12 | 2011-06-23 | University Of Massachusetts | Zwitterionic polymers with therapeutic moieties |
US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US20100158850A1 (en) | 2008-12-23 | 2010-06-24 | The Regents Of The University Of Michigan | Dendrimer based modular platforms |
EP2411407A1 (en) | 2009-03-27 | 2012-02-01 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
WO2010126552A1 (en) | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
EP2432476A4 (en) | 2009-05-01 | 2013-03-20 | Ophthotech Corp | METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES |
CN101575402B (zh) | 2009-05-31 | 2012-06-27 | 中国科学院化学研究所 | 一种多臂星型聚合物及其制备方法 |
EP2260873B1 (en) | 2009-06-08 | 2019-07-24 | Biocompatibles UK Limited | Pcylation of proteins |
BRPI1012321A8 (pt) | 2009-06-17 | 2016-09-27 | Abbott Biotherapeutics Corp | Anticorpos anti-vegf e seus usos |
EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
CN102025901A (zh) | 2009-09-23 | 2011-04-20 | 国基电子(上海)有限公司 | 相机模组及其检测方法 |
US20110165648A1 (en) | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
WO2011066417A2 (en) | 2009-11-24 | 2011-06-03 | Carnegie Mellon University | Antibodies and conjugates for modulators of angiogenesis |
JP5818805B2 (ja) | 2009-12-11 | 2015-11-18 | ジェネンテック, インコーポレイテッド | 抗vegf−c抗体及びその使用方法 |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
JP2013519699A (ja) | 2010-02-16 | 2013-05-30 | ノヴォ ノルディスク アー/エス | 因子viii融合タンパク質 |
CN102770449B (zh) | 2010-02-16 | 2016-02-24 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
KR20180130008A (ko) | 2010-04-15 | 2018-12-05 | 올리가시스 | 고분자량 쌍성이온-함유 중합체 |
JP2012025820A (ja) | 2010-07-21 | 2012-02-09 | Kansai Paint Co Ltd | 親水化処理剤組成物 |
US9065060B2 (en) | 2011-01-17 | 2015-06-23 | Lg Chem, Ltd. | Compound and organic light-emitting device comprising same |
AU2012245205B2 (en) | 2011-04-21 | 2017-06-01 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
WO2013059137A1 (en) | 2011-10-17 | 2013-04-25 | Oligasis | High molecular weight zwitterion-containing polymers |
WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
CA2869473C (en) | 2012-04-03 | 2020-06-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor bb antibodies and uses thereof |
JP6234064B2 (ja) | 2012-05-23 | 2017-11-22 | キヤノン株式会社 | 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法 |
JP5846044B2 (ja) | 2012-05-23 | 2016-01-20 | 日油株式会社 | (メタ)アクリル酸誘導体の製造方法 |
EP2906693A1 (en) | 2012-10-15 | 2015-08-19 | Novo Nordisk Health Care AG | Coagulation factor vii polypeptides |
AR095437A1 (es) | 2013-03-13 | 2015-10-14 | Genzyme Corp | Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso |
CN103193819A (zh) | 2013-03-13 | 2013-07-10 | 苏州蔻美新材料有限公司 | 一锅法合成mpc的方法 |
ES2891755T3 (es) | 2013-06-06 | 2022-01-31 | Pf Medicament | Anticuerpos anti-C10orf54 y utilizaciones de los mismos |
CN103421039B (zh) | 2013-09-03 | 2015-12-23 | 重庆工商大学 | 2-甲基丙烯酰氧基乙基磷酰胆碱的合成方法 |
PT3041513T (pt) | 2013-09-08 | 2020-09-07 | Kodiak Sciences Inc | Conjugados de polímeros zwiteriónicos com fator viii |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CA2953698A1 (en) | 2014-06-28 | 2015-12-30 | Kodiak Sciences Inc. | Dual pdgf/vegf antagonists |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
GB2551979A (en) | 2016-06-30 | 2018-01-10 | Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd | Cleavable polymer drug conjugates |
CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
KR20200140817A (ko) | 2018-03-02 | 2020-12-16 | 코디악 사이언시스 인코포레이티드 | Il-6 항체 그리고 이의 융합 작제물 및 접합체 |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
-
2010
- 2010-05-10 WO PCT/US2010/034252 patent/WO2011075185A1/en active Application Filing
- 2010-05-10 US US13/515,913 patent/US8765432B2/en active Active
- 2010-12-20 EP EP10838353.0A patent/EP2512462B1/en active Active
- 2010-12-20 EP EP20151266.2A patent/EP3659591B1/en active Active
- 2010-12-20 DK DK10838353.0T patent/DK2512462T3/en active
- 2010-12-20 MX MX2012006970A patent/MX346423B/es active IP Right Grant
- 2010-12-20 WO PCT/US2010/061358 patent/WO2011075736A1/en active Application Filing
- 2010-12-20 KR KR1020127018788A patent/KR101852044B1/ko active IP Right Grant
- 2010-12-20 PT PT108383530T patent/PT2512462T/pt unknown
- 2010-12-20 CN CN201080062252.7A patent/CN102811713B/zh active Active
- 2010-12-20 BR BR112012014556-8A patent/BR112012014556B1/pt active IP Right Grant
- 2010-12-20 DK DK17181272.0T patent/DK3254678T3/da active
- 2010-12-20 EP EP17181272.0A patent/EP3254678B1/en active Active
- 2010-12-20 JP JP2012544945A patent/JP5760007B2/ja active Active
- 2010-12-20 PT PT171812720T patent/PT3254678T/pt unknown
- 2010-12-20 CA CA2783615A patent/CA2783615C/en active Active
- 2010-12-20 CA CA3039426A patent/CA3039426C/en active Active
- 2010-12-20 AU AU2010330727A patent/AU2010330727B2/en active Active
- 2010-12-20 US US13/516,173 patent/US20130045522A1/en not_active Abandoned
- 2010-12-20 CN CN201610439969.8A patent/CN106075466A/zh active Pending
-
2012
- 2012-06-15 CL CL2012001621A patent/CL2012001621A1/es unknown
- 2012-07-16 CO CO12119310A patent/CO6592052A2/es not_active Application Discontinuation
-
2014
- 2014-04-29 US US14/265,174 patent/US20150004128A1/en not_active Abandoned
-
2015
- 2015-06-08 JP JP2015115642A patent/JP5990629B2/ja active Active
-
2016
- 2016-04-14 US US15/099,234 patent/US11819531B2/en active Active
- 2016-06-14 US US15/182,278 patent/US20170007710A1/en not_active Abandoned
- 2016-08-15 JP JP2016159104A patent/JP6416832B2/ja active Active
-
2018
- 2018-06-04 HK HK18107293.9A patent/HK1247828A1/zh unknown
- 2018-10-04 JP JP2018189049A patent/JP6777706B2/ja active Active
-
2020
- 2020-10-08 JP JP2020170314A patent/JP2021021075A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1247828A1 (zh) | 多功能兩性離子聚合物共軛物 | |
IL286056B1 (en) | coupling methods | |
IL216719A0 (en) | Pure-peg-lipid conjugates | |
IL211180B (en) | Attached polyethylene glycol and docetaxel | |
EP2507287A4 (en) | NOVEL PHOTOACTIVE POLYMER | |
GB0915769D0 (en) | Stabplate connections | |
IL259430B (en) | Glycosylated molecule-motif-repeat conjugates | |
GB201012111D0 (en) | Cyclosporin conjugates | |
GB0914038D0 (en) | Connection | |
PT2398854T (pt) | Preparação melhorada de polímero | |
GB0922354D0 (en) | Novel polymer conjugates | |
EP2406304A4 (en) | ANTHRACYCLINE-LIPID CONJUGATES WITH GABA BINDING | |
GB0908053D0 (en) | Novel polymers | |
GB0906023D0 (en) | Insulin-Nanoparticle conjugates | |
SI2509593T1 (sl) | Protein-polimer konjugati | |
GB0920356D0 (en) | Stabplate connections | |
GB0910413D0 (en) | Polymerization | |
PL389801A1 (pl) | Urządzenie wielofunkcyjne | |
AU2009900328A0 (en) | Functional Polymers | |
TWM372389U (en) | Multifunctional pedal | |
GB0918357D0 (en) | Bébé connection | |
GB0908139D0 (en) | Mechanical seal-securing | |
AU2009903739A0 (en) | Ostomates underware | |
TWM371715U (en) | Foot-sensitive trash can |